Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics
CompanyDeals

Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers
CompanyDeals

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers

Sino Biopharmaceutical's TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment
CompanyDrug

Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment

3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases
CompanyDeals

3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases

Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
CompanyDeals

Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia

bioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline
CompanyDeals

BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline

Suzhou GenAssist's GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
CompanyDrug

Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy

BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development
CompanyDeals

BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology
CompanyDeals

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC
CompanyDeals

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC

AbbVie's Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
CompanyDrug

AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial

Harbour BioMed Wins CNIPA Validation of 'Binding Molecule' Patent Amid Dispute
CompanyLegal / IP

Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute